A new method to replace defective genes in Duchenne muscular dystrophy
A Novel Technology for Full-Length Gene Replacement Therapy of Duchenne Muscular Dystrophy
This study is testing a new treatment for Duchenne muscular dystrophy (DMD) that uses a harmless virus to deliver a healthy version of a gene to help your muscles work better and stay strong.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Salk Institute for Biological Studies NIH-funded |
| Lab location | 1 site (La Jolla, UNITED STATES) |
| Project ID | NIH-11004357 on NIH RePORTER |
What this research studies
This research focuses on developing a gene replacement therapy for Duchenne muscular dystrophy (DMD), a severe genetic disorder that leads to muscle degeneration. The approach utilizes Adeno-Associated Viruses (AAV) to deliver a healthy copy of the dystrophin gene directly to muscle cells, aiming to restore their function and prevent further degeneration. By replacing the defective gene rather than editing it, this method seeks to overcome challenges associated with current gene-editing technologies. Patients may be monitored for improvements in muscle function and overall health as part of the therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are males diagnosed with Duchenne muscular dystrophy, particularly those with specific mutations in the dystrophin gene.
Not a fit: Patients with forms of muscular dystrophy other than Duchenne muscular dystrophy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a potential cure for Duchenne muscular dystrophy, significantly improving the quality of life and longevity for affected individuals.
How similar studies have performed: Previous research has shown promise in gene replacement therapies for other genetic disorders, indicating potential success for this novel approach in treating DMD.
Where this research is happening
La Jolla, UNITED STATES
- Salk Institute for Biological Studies — La Jolla, United States (Active)
Researchers
- Principal investigator: Hsu, Ryan Hon Hean — Salk Institute for Biological Studies
- Study coordinator: Hsu, Ryan Hon Hean
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.